Indication
Refractory oropharyngeal candidiasis
Refractory oropharyngeal candidiasis is a persistent or recurrent fungal infection of the oral and pharyngeal mucosa that fails to respond clinically to standard first-line antifungal therapy, typically oral fluconazole or itraconazole. Read more about Refractory oropharyngeal candidiasis
3 drugs 3 manufacturers
Drugs that treat it
Common Refractory oropharyngeal candidiasis therapies.
NOXAFIL (posaconazole)
POSACONAZOLE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRefractory oropharyngeal candidiasis is a persistent or recurrent fungal infection of the oral and pharyngeal mucosa that fails to respond clinically to standard first-line antifungal therapy, typically oral fluconazole or itraconazole.
Most commonly affecting severely immunocompromised populations—such as individuals with advanced HIV/AIDS, hematologic malignancies, or profound chemotherapy-induced immunosuppression—the condition is typically caused by *Candida albicans* or non-*albicans Candida* species demonstrating intrinsic or acquired antifungal resistance.
Clinically, it presents with painful, persistent erythema or pseudomembranous white mucosal plaques that can lead to severe dysgeusia, odynophagia, and impaired oral intake, necessitating alternative systemic antifungal management.
- jefferson.edu
Refractory oropharyngeal candidiasis is a persistent or recurrent fungal infection of the oral and pharyngeal mucosa that fails to respond clinically to standard first-line antifungal therapy, typically oral fluconazole or itraconazole Most commonly affecting severely immunocompromised populations—such as individuals with advanced HIV/AIDS, hematologic malignancies, or profound chemotherapy-induced immunosuppression—the condition is typically caused by *Candida albicans* or non-*albicans Candida...
- nih.gov
Refractory oropharyngeal candidiasis is a persistent or recurrent fungal infection of the oral and pharyngeal mucosa that fails to respond clinically to standard first-line antifungal therapy, typically oral fluconazole or itraconazole Most commonly affecting severely immunocompromised populations—such as individuals with advanced HIV/AIDS, hematologic malignancies, or profound chemotherapy-induced immunosuppression—the condition is typically caused by *Candida albicans* or non-*albicans Candida...
- nih.gov
Most commonly affecting severely immunocompromised populations—such as individuals with advanced HIV/AIDS, hematologic malignancies, or profound chemotherapy-induced immunosuppression—the condition is typically caused by *Candida albicans* or non-*albicans Candida* species demonstrating intrinsic or acquired antifungal resistance Clinically, it presents with painful, persistent erythema or pseudomembranous white mucosal plaques that can lead to severe dysgeusia, odynophagia, and impaired oral in...
- nih.gov
Clinically, it presents with painful, persistent erythema or pseudomembranous white mucosal plaques that can lead to severe dysgeusia, odynophagia, and impaired oral intake, necessitating alternative systemic antifungal management
Personalize your experience
Follow Refractory oropharyngeal candidiasis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.